Technophage’s efforts to tackle COVID-19 in 2021

Technophage’s efforts to tackle COVID-19 in 2021

4 Ago 2021 | News

During this last year, Technophage has been dedicated to the development of a new biologic product for COVID-19. The company has been working together with Medinfar Group in a joint effort to make available a new biologic that will help to tackle this devastating...
Technophage is hiring a lab technician

Technophage is hiring a lab technician

27 Mai 2021 | Careers

TechnoPhage is hiring a Laboratory Technician to support research activities and conduct laboratory tasks within a team dedicated to the research and development of new biologic medicines. Main activities: Support scientific experiments. Execute routine...
Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

14 Mai 2021 | Press release

Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first bacteriophage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria (Pseudomonas...